Igor Dolgalev - Related publications

New York University School of Medicine, New York, NY, United States 
 Memorial Sloan Kettering Cancer Center, Rockville Centre, NY, United States 
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
50 most relevant papers in past 60 days:
Year Citation  Score
2021 Hijazo-Pechero S, Alay A, Marín R, Vilariño N, Muñoz-Pinedo C, Villanueva A, Santamaría D, Nadal E, Solé X. Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. Cancers. 13. PMID 34638221 DOI: 10.3390/cancers13194734   
2021 Hao N, Zhou Y, Li Y, Zhang H, Wang B, Liu X, Ren Y, He J, Zhou C, Tang X. Clinical Value and Potential Mechanisms of Oxysterol-Binding Protein Like 3 (OSBPL3) in Human Tumors. Frontiers in Molecular Biosciences. 8: 739978. PMID 34738015 DOI: 10.3389/fmolb.2021.739978   
2021 Xu Z, Hu K, Bailey P, Springfeld C, Roth S, Kurilov R, Brors B, Gress T, Buchholz M, An J, Wei K, Peccerella T, Büchler MW, Hackert T, Neoptolemos JP. Clinical Impact of Molecular Subtyping of Pancreatic Cancer. Frontiers in Cell and Developmental Biology. 9: 743908. PMID 34805152 DOI: 10.3389/fcell.2021.743908   
2021 Chang Y, Wang Y, Li B, Lu X, Wang R, Li H, Yan B, Gu A, Wang W, Huang A, Wu S, Li R. Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer. Frontiers in Genetics. 12: 722078. PMID 34616428 DOI: 10.3389/fgene.2021.722078   
2021 Fisk JN, Mahal AR, Dornburg A, Gaffney SG, Aneja S, Contessa JN, Rimm D, Yu JB, Townsend JP. Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters. PMID 34780851 DOI: 10.1016/j.canlet.2021.11.011   
2021 Wu Y, Chen Q, Zhang Q, Li M, Li H, Jia L, Huang Y, Zhang J. Analysis of whole-exome data of cfDNA and the tumor tissue of non-small cell lung cancer. Annals of Translational Medicine. 9: 1453. PMID 34734005 DOI: 10.21037/atm-21-4117   
2021 Merkle J, Breunig M, Schmid M, Allgöwer C, Krüger J, Melzer MK, Bens S, Siebert R, Perkhofer L, Azoitei N, Seufferlein T, Heller S, Meier M, Müller M, Kleger A, et al. -Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome. Cancers. 13. PMID 34680288 DOI: 10.3390/cancers13205139   
2021 Nguyen PT, Coetzee SG, Lakeland DL, Hazelett DJ. A molecular taxonomy of tumors independent of tissue-of-origin. Iscience. 24: 103084. PMID 34611608 DOI: 10.1016/j.isci.2021.103084   
2021 Guo ZS, Qu Z. PDLIM2: Signaling pathways and functions in cancer suppression and host immunity. Biochimica Et Biophysica Acta. Reviews On Cancer. 1876: 188630. PMID 34571051 DOI: 10.1016/j.bbcan.2021.188630   
2021 Li J, Yu CP, Li Q, Chang S, Xie LL, Wang S. Large-scale omics data reveal the cooperation of mutation-circRNA-miRNA-target gene network in liver cancer oncogenesis. Future Oncology (London, England). PMID 34677082 DOI: 10.2217/fon-2021-0940   
2021 McNulty SN, Schwetye KE, Ferguson C, Storer CE, Ansstas G, Kim AH, Gutmann DH, Rubin JB, Head RD, Dahiya S. BRAF mutations may identify a clinically distinct subset of glioblastoma. Scientific Reports. 11: 19999. PMID 34625582 DOI: 10.1038/s41598-021-99278-w   
2021 Bagheri-Yarmand R, Busaidy NL, McBeath E, Danysh BP, Evans KW, Moss TJ, Akcakanat A, Ng PKS, Knippler CM, Golden JA, Williams MD, Multani AS, Cabanillas ME, Shaw KR, Meric-Bernstam F, et al. Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. Cancers. 13. PMID 34638434 DOI: 10.3390/cancers13194950   
2021 Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, et al. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology (London, England). PMID 34723634 DOI: 10.2217/fon-2021-0752   
2021 Kim SY, Johns SC, Gupta P, Varki N, Fuster MM. Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia. Neoplasia (New York, N.Y.). 23: 1137-1143. PMID 34715561 DOI: 10.1016/j.neo.2021.09.008   
2021 Lin JC, Liu TP, Andriani V, Athoillah M, Wang CY, Yang PM. Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant or Wild-Type Gene. Journal of Personalized Medicine. 11. PMID 34834551 DOI: 10.3390/jpm11111199   
2021 Ma L, Diao B, Huang Z, Wang B, Yu J, Meng X. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Communications (London, England). PMID 34699691 DOI: 10.1002/cac2.12229   
2021 Devor EJ, Schickling BM, Lapierre JR, Bender DP, Gonzalez-Bosquet J, Leslie KK. The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells. Pharmaceuticals (Basel, Switzerland). 14. PMID 34577642 DOI: 10.3390/ph14090942   
2021 Cheng L, Creasy T, Pilataxi F, Greenlees L, Vence L, Sridhar S, Streicher K. Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma. Cancer Immunology, Immunotherapy : Cii. PMID 34623465 DOI: 10.1007/s00262-021-03065-5   
2021 Rieger I, Tsintari V, Overkamp M, Fend F, Lopez CD, Schittenhelm MM, Kampa-Schittenhelm KM. ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. Frontiers in Molecular Biosciences. 8: 727203. PMID 34805267 DOI: 10.3389/fmolb.2021.727203   
2021 Shao Q, Wang L, Yuan M, Jin X, Chen Z, Wu C. TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism. Frontiers in Immunology. 12: 688961. PMID 34659197 DOI: 10.3389/fimmu.2021.688961   
2021 Pauli C, De Boni L, Pauwels JE, Chen Y, Planas-Paz L, Shaw R, Emerling BM, Grandori C, Hopkins BD, Rubin MA. A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients. Molecular Cancer Research : McR. PMID 34728552 DOI: 10.1158/1541-7786.MCR-21-0255   
2021 Song TY, Long M, Zhao HX, Zou MW, Fan HJ, Liu Y, Geng CL, Song MF, Liu YF, Chen JY, Yang YL, Zhou WR, Huang DW, Peng B, Peng ZG, et al. Tumor evolution selectively inactivates the core microRNA machinery for immune evasion. Nature Communications. 12: 7003. PMID 34853298 DOI: 10.1038/s41467-021-27331-3   
2021 Xie X, Tang Y, Sheng J, Shu P, Zhu X, Cai X, Zhao C, Wang L, Huang X. Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology. 9: 761758. PMID 34746153 DOI: 10.3389/fcell.2021.761758   
2021 Chen GT, Tifrea DF, Murad R, Habowski AN, Lyou Y, Duong MR, Hosohama L, Mortazavi A, Edwards RA, Waterman ML. Disruption of beta-catenin dependent Wnt signaling in colon cancer cells remodels the microenvironment to promote tumor invasion. Molecular Cancer Research : McR. PMID 34799404 DOI: 10.1158/1541-7786.MCR-21-0349   
2021 Saiz-Ladera C, Baliu-Piqué M, Cimas FJ, Manzano A, García-Barberán V, Camarero SC, Hinojal GF, Pandiella A, Győrffy B, Stewart D, Cruz-Hernández JJ, Pérez-Segura P, Ocana A. Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. Frontiers in Oncology. 11: 714550. PMID 34692491 DOI: 10.3389/fonc.2021.714550   
2021 Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, et al. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Reports. Medicine. 2: 100411. PMID 34755131 DOI: 10.1016/j.xcrm.2021.100411   
2021 Pellerino A, Bruno F, Rudà R, Soffietti R. Systemic Therapy for Lung Cancer Brain Metastases. Current Treatment Options in Oncology. 22: 110. PMID 34693454 DOI: 10.1007/s11864-021-00911-7   
2021 Patel M, Uboha NV. Treatment Approach to Adenocarcinoma of the Ampulla of Vater. Current Treatment Options in Oncology. 22: 103. PMID 34586537 DOI: 10.1007/s11864-021-00894-5   
2021 Attaran S, Bissell MJ. The Role of Tumor Microenvironment and Exosomes in Dormancy and Relapse. Seminars in Cancer Biology. PMID 34757184 DOI: 10.1016/j.semcancer.2021.09.008   
2021 Zhou R, Feng Y, Ye J, Han Z, Liang Y, Chen Q, Xu X, Huang Y, Jia Z, Zhong W. Prediction of Biochemical Recurrence-Free Survival of Prostate Cancer Patients Leveraging Multiple Gene Expression Profiles in Tumor Microenvironment. Frontiers in Oncology. 11: 632571. PMID 34631510 DOI: 10.3389/fonc.2021.632571   
2021 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. Journal of Clinical Laboratory Analysis. e24141. PMID 34817097 DOI: 10.1002/jcla.24141   
2021 Jun E, Koo B, Kim EJ, Hwang DW, Lee JH, Song KB, Lee W, Park Y, Hong S, Shin Y, Kim SC. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer. Biomedicines. 9. PMID 34829828 DOI: 10.3390/biomedicines9111599   
2021 Kumari S, Advani D, Sharma S, Ambasta RK, Kumar P.. Combinatorial therapy in tumor microenvironment: Where do we stand?. 2021 Jul 2; [Epub ahead of print] Review. PubMed PMID: Biochim Biophys Acta Rev Cancer.. 1876: 188585. PMID 34224836 DOI: doi: 10.1016/j.bbcan.2021.188585.   
2021 Bashash D, Zandi Z, Kashani B, Pourbagheri-Sigaroodi A, Salari S, Ghaffari SH. Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. Journal of Cellular Physiology. PMID 34498289 DOI: 10.1002/jcp.30575   
2021 Sato H, Saito T, Horii H, Kajiura M, Kikuchi N, Takada N, Taguchi K, Yoshida M, Hasegawa M, Taguchi H, Yoshida Y, Ando K, Fujiya M, Omori Y, Hank T, et al. Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis. Frontiers in Genetics. 12: 608324. PMID 34616420 DOI: 10.3389/fgene.2021.608324   
2021 Li L, Wei H, Zhang YW, Zhao S, Che G, Wang Y, Chen L. Differential expression of long non-coding RNAs as diagnostic markers for lung cancer and other malignant tumors. Aging. 13. PMID 34670194 DOI: 10.18632/aging.203523   
2021 Su K, Yu Q, Shen R, Sun SY, Moreno CS, Li X, Qin ZS. Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Cell Reports Methods. 1. PMID 34671755 DOI: 10.1016/j.crmeth.2021.100050   
2021 Li X, Liang W, Zhao H, Jin Z, Shi G, Xie W, Wang H, Wu X. Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy. Frontiers in Cell and Developmental Biology. 9: 749157. PMID 34805159 DOI: 10.3389/fcell.2021.749157   
2021 Dooley S, Tobillo R, de Joya E, Freedman LM, Samuels S, Sargi ZB, Weed D, Perez C, Samuels MA, Carmona R. Destructive-Type TP53 Mutations are Independently Associated With Worse Overall Survival in Patients With HPV-Negative Head and Neck Squamous Cell Carcinoma. International Journal of Radiation Oncology, Biology, Physics. 111: e368-e369. PMID 34701286 DOI: 10.1016/j.ijrobp.2021.07.1091   
2021 Zboril E, Yoo H, Chen L, Liu Z. Dynamic Interactions of Transcription Factors and Enhancer Reprogramming in Cancer Progression. Frontiers in Oncology. 11: 753051. PMID 34616687 DOI: 10.3389/fonc.2021.753051   
2021 Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, et al. Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. Cancer Research. PMID 34610968 DOI: 10.1158/0008-5472.CAN-21-1033   
2021 Sun X, Chen Q, Zhang L, Chen J, Zhang X. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines. Mathematical Biosciences and Engineering : Mbe. 18: 6262-6287. PMID 34517533 DOI: 10.3934/mbe.2021313   
2021 Yan M, Hu J, Ping Y, Xu L, Liao G, Jiang Z, Pang B, Sun S, Zhang Y, Xiao Y, Li X. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma. Frontiers in Immunology. 12: 758288. PMID 34804045 DOI: 10.3389/fimmu.2021.758288   
2021 He Y, Rivera J, Diossy M, Duan H, Bowman-Colin C, Reed R, Jennings R, Novak J, Tran SV, Cohen EF, Szuts D, Giobbie-Hurder A, Bronson RT, Bass AJ, Signoretti S, et al. heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34607954 DOI: 10.1073/pnas.2108421118   
2021 Rashid M, Ali R, Almuzzaini B, Song H, Al Hallaj A, Abdulkarim AA, Mohamed Baz O, Al Zahrani H, Mustafa Sabeena M, Alharbi W, Hussein M, Boudjelal M. Discovery of a novel potentially transforming somatic mutation in CSF2RB gene in breast cancer. Cancer Medicine. PMID 34729943 DOI: 10.1002/cam4.4106   
2021 Chen X, Song J, Wang X, Sun D, Liu Y, Jiang Y. LncRNA LINC00460: Function and mechanism in human cancer. Thoracic Cancer. PMID 34821482 DOI: 10.1111/1759-7714.14238   
2021 Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Current Opinion in Immunology. 74: 25-31. PMID 34619458 DOI: 10.1016/j.coi.2021.09.002   
2021 Lee M, Untch BR, Xu B, Ghoissein R, Han C, Kuo F, Valero C, Nadeem Z, Patel N, Makarov V, Dogan S, Wong RJ, Sherman EJ, Ho AL, Chan TA, et al. Genomic and transcriptomic correlates of thyroid carcinoma evolution after BRAF inhibitor therapy. Molecular Cancer Research : McR. PMID 34635506 DOI: 10.1158/1541-7786.MCR-21-0442   
2021 Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, et al. Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated -mutated advanced non-small cell lung cancer: a prospective observational study. Translational Lung Cancer Research. 10: 3582-3593. PMID 34584858 DOI: 10.21037/tlcr-21-461   
2021 Cui Y, Li H, Zhan H, Han T, Dong Y, Tian C, Guo Y, Yan F, Dai D, Liu P. Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics. Frontiers in Oncology. 11: 733478. PMID 34604069 DOI: 10.3389/fonc.2021.733478